Dan-Qian Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3477401/publications.pdf

Version: 2024-02-01

41 papers	3,737 citations	159585 30 h-index	289244 40 g-index
41 all docs	41 docs citations	41 times ranked	3405 citing authors

#	Article	IF	Citations
1	1â€Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway. British Journal of Pharmacology, 2022, 179, 103-124.	5.4	28
2	Natural Products Against Renal Fibrosis via Modulation of SUMOylation. Frontiers in Pharmacology, 2022, 13, 800810.	3.5	1
3	Serum Metabolites Associated with Blood Pressure in Chronic Kidney Disease Patients. Metabolites, 2022, 12, 281.	2.9	1
4	Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice. Acta Pharmacologica Sinica, 2022, 43, 2929-2945.	6.1	23
5	A Review of Traditional Chinese Medicine in Treating Renal Interstitial Fibrosis via Endoplasmic Reticulum Stress-Mediated Apoptosis. BioMed Research International, 2021, 2021, 1-10.	1.9	2
6	The Active Compounds and Therapeutic Target of Tripterygium wilfordii Hook. f. in Attenuating Proteinuria in Diabetic Nephropathy: A Review. Frontiers in Medicine, 2021, 8, 747922.	2.6	13
7	Sirt3 Maintains Microvascular Endothelial Adherens Junction Integrity to Alleviate Sepsis-Induced Lung Inflammation by Modulating the Interaction of VE-Cadherin and Î²-Catenin. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	4.0	8
8	Small molecule inhibitors of epithelialâ€mesenchymal transition for the treatment of cancer and fibrosis. Medicinal Research Reviews, 2020, 40, 54-78.	10.5	93
9	Poricoic acid A as a modulator of TPH-1 expression inhibits renal fibrosis via modulating protein stability of Î²-catenin and Î²-catenin-mediated transcription. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096264.	2.5	17
10	Identification of endogenous 1â€aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. British Journal of Pharmacology, 2020, 177, 3415-3435.	5.4	50
11	Poricoic acid A activates AMPK to attenuate fibroblast activation and abnormal extracellular matrix remodelling in renal fibrosis. Phytomedicine, 2020, 72, 153232.	5.3	28
12	Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and Î²-catenin pathway in AKI-to-CKD continuum. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986911.	2.5	38
13	Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/Axl NF ÎºB/Nrf2 axis. Free Radical Biology and Medicine, 2019, 134, 484-497.	2.9	76
14	Microbiomeâ€“metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cellular and Molecular Life Sciences, 2019, 76, 4961-4978.	5.4	146
15	Activated NF-ÎºB/Nrf2 and Wnt/Î²-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2317-2332.	3.8	42
16	The Matrix Metalloproteinaseâ€13 Inhibitor Poricoic Acid ZI Ameliorates Renal Fibrosis by Mitigating Epithelialâ€Mesenchymal Transition. Molecular Nutrition and Food Research, 2019, 63, e1900132.	3.3	33
17	Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. Experimental and Molecular Medicine, 2019, 51, 1-18.	7.7	90
18	Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nature Communications, 2019, 10, 1476.	12.8	171

#	Article	IF	Citations
19	Microbiomeâ€“metabolome reveals the contribution of gutâ€“kidney axis on kidney disease. Journal of Translational Medicine, 2019, 17, 5.	4.4	233
20	Novel inhibitors of the cellular reninâ€angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/Î²â€catenin pathway against renal fibrosis. British Journal of Pharmacology, 2018, 175, 2689-2708.	5.4	154
21	Novel RAS Inhibitors Poricoic Acid ZG and Poricoic Acid ZH Attenuate Renal Fibrosis via a Wnt/Î²-Catenin Pathway and Targeted Phosphorylation of smad3 Signaling. Journal of Agricultural and Food Chemistry, 2018, 66, 1828-1842.	5.2	115
22	Proteomics for Biomarker Identification and Clinical Application in Kidney Disease. Advances in Clinical Chemistry, 2018, 85, 91-113.	3.7	41
23	Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-Î²-mediated Smad3 phosphorylation. Phytomedicine, 2018, 42, 207-218.	5.3	93
24	Central role of dysregulation of TGF-Î²/Smad in CKD progression and potential targets of its treatment. Biomedicine and Pharmacotherapy, 2018, 101, 670-681.	5.6	250
25	Natural Products as a Source for Antifibrosis Therapy. Trends in Pharmacological Sciences, 2018, 39, 937-952.	8.7	162
26	Natural products for the prevention and treatment of kidney disease. Phytomedicine, 2018, 50, 50-60.	5.3	92
27	Rhubarb Protect Against Tubulointerstitial Fibrosis by Inhibiting TGF-Î²/Smad Pathway and Improving Abnormal Metabolome in Chronic Kidney Disease. Frontiers in Pharmacology, 2018, 9, 1029.	3.5	55
28	New insights into TGF-Î²/Smad signaling in tissue fibrosis. Chemico-Biological Interactions, 2018, 292, 76-83.	4.0	671
29	Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/Î²-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease. Redox Biology, 2017, 12, 505-521.	9.0	146
30	The link between phenotype and fatty acid metabolism in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 1154-1166.	0.7	91
31	Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism. Journal of Proteome Research, 2017, 16, 1566-1578.	3.7	108
32	Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites. Clinical Biochemistry, 2017, 50, 1078-1086.	1.9	37
33	Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-Î²/Smad signaling pathway. Phytomedicine, 2017, 36, 243-253.	5.3	84
34	Urinary biomarker and treatment mechanism of Rhizoma Alismatis on hyperlipidemia. Biomedical Chromatography, 2017, 31, e3829.	1.7	37
35	Role of RAS/Wnt/Î²-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. Chemico-Biological Interactions, 2017, 273, 56-72.	4.0	91
36	Metabolomic application in toxicity evaluation and toxicological biomarker identification of natural product. Chemico-Biological Interactions, 2016, 252, 114-130.	4.0	74

#	Article	IF	Citations
37	Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biology, 2016, 10, 168-178.	9.0	148
38	A Pharmaco-Metabonomic Study on Chronic Kidney Disease and Therapeutic Effect of Ergone by UPLC-QTOF/HDMS. PLoS ONE, 2014, 9, e115467.	2.5	55
39	Diuretic and anti-diuretic activities of fractions of Alismatis rhizoma. Journal of Ethnopharmacology, 2014, 157, 114-118.	4.1	70
40	Diuretic and anti-diuretic activities of the ethanol and aqueous extracts of Alismatis rhizoma. Journal of Ethnopharmacology, 2014, 154, 386-390.	4.1	64
41	Cloud-Point Extraction Combined with Liquid Chromatography for the Determination of Ergosterol, a Natural Product with Diuretic Activity, in Rat Plasma, Urine, and Faeces. Journal of Analytical Methods in Chemistry, 2013, 2013, 1-8.	1.6	6